Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ALLK Stock Summary
Top 10 Correlated ETFs
ALLK
In the News
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.
Why Is Allakos (ALLK) Stock Down 57% Today?
Allakos (NASDAQ: ALLK ) stock is taking a beating on Tuesday after the clinical stage biopharmaceutical company revealed results from its latest study. The bad news here comes from the company's Phase 2 and Phase 2b clinical trials of lirentelimab.
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.
Allakos to stop further development of skin disease drug, plans job cuts
Allakos Inc said on Tuesday that it plans to discontinue the development of its experimental skin disease drug after it failed two mid-stage studies.
Why Shares of Allakos Are Up Wednesday
An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoimmune skin disorders.
Scratching The Surface: Allakos' Novel Take On Urticaria
Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for omalizumab-refractory patients, but late-phase results are keys to the drug's validation. Investment Recommendation: Speculative "Buy" advised for bold investors. Initiate starter positions, closely monitor upcoming Phase 2b data and cash burn rate.
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.
Why Allakos Stock Skyrocketed Nearly 9% Higher Today
An analyst bumped his recommendation higher. This closely followed an encouraging quarterly earnings report/business update from the biotech.
Why Allakos Stock Was Heating Up Today
Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An analyst thinks these twin catalysts could cause the biotech's shares to more than quadruple in value.
Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade
Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ALLK Financial details
ALLK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.72 | -2.98 | -4.96 | -5.02 | -2.14 | |
Operating cash flow per share | -1.39 | -2.3 | -3.86 | -4.42 | -1.34 | |
Free cash flow per share | -1.41 | -2.31 | -4.48 | -4.56 | -1.35 | |
Cash per share | 10.97 | 13.32 | 7.88 | 4.42 | 1.97 | |
Book value per share | 10.97 | 13.22 | 8.28 | 4.91 | 1.94 | |
Tangible book value per share | 10.97 | 13.22 | 8.28 | 4.91 | 1.94 | |
Share holders equity per share | 10.97 | 13.22 | 8.28 | 4.91 | 1.94 | |
Interest debt per share | 0.33 | 0.87 | 0.96 | 0.83 | 0.48 | |
Market cap | 4.31B | 6.93B | 527.02M | 532.85M | 236.96M | |
Enterprise value | 4.28B | 6.76B | 423.29M | 494.74M | 211.98M | |
P/E ratio | -55.49 | -46.94 | -1.97 | -1.68 | -1.28 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -68.39 | -60.82 | -2.54 | -1.9 | -2.03 | |
PFCF ratio | -67.56 | -60.49 | -2.19 | -1.85 | -2.02 | |
P/B Ratio | 8.69 | 10.59 | 1.18 | 1.72 | 1.4 | |
PTB ratio | 8.69 | 10.59 | 1.18 | 1.72 | 1.4 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -46.81 | -43.07 | -1.56 | -1.53 | -1.12 | |
EV to operating cash flow | -67.92 | -59.38 | -2.04 | -1.77 | -1.82 | |
EV to free cash flow | -67.1 | -59.05 | -1.76 | -1.72 | -1.81 | |
Earnings yield | -0.02 | -0.02 | -0.51 | -0.6 | -0.78 | |
Free cash flow yield | -0.01 | -0.02 | -0.46 | -0.54 | -0.49 | |
Debt to equity | 0.02 | 0.07 | 0.12 | 0.16 | 0.25 | |
Debt to assets | 0.02 | 0.06 | 0.1 | 0.13 | 0.17 | |
Net debt to EBITDA | 0.33 | 1.05 | 0.38 | 0.12 | 0.13 | |
Current ratio | 38.27 | 29.81 | 11.22 | 10.28 | 4.92 | |
Interest coverage | -14.74 | 0 | 0 | -87.78 | 0 | |
Income quality | 0.74 | 0.74 | 0.77 | 0.88 | 0.63 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0.16 | 0.03 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.51 | -0.41 | -14.38 | -1.18 | -0.1 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 20.6 | 29.79 | 30.4 | 23.53 | 9.68 | |
ROIC | -0.16 | -0.2 | -0.49 | -0.79 | -0.79 | |
Return on tangible assets | -0.15 | -0.21 | -0.5 | -0.82 | -0.76 | |
Graham Net | 10.5 | 12 | 6.22 | 3.22 | 1.11 | |
Working capital | 486.81M | 646.82M | 411.33M | 278.81M | 143.31M | |
Tangible asset value | 495.72M | 654.4M | 445.48M | 310.43M | 168.82M | |
Net current asset value | 478.7M | 604.04M | 362.23M | 232.86M | 105.1M | |
Invested capital | 0.02 | 0.07 | 0.12 | 0.16 | 0.25 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 4.03M | 9.96M | 13.83M | 9.26M | 3.3M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.44K | 2.18K | 1.02K | 176.81 | 104.85 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.25 | 0.17 | 0.36 | 2.06 | 3.48 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.16 | -0.23 | -0.6 | -1.02 | -1.1 | |
Capex per share | -0.02 | -0.01 | -0.62 | -0.13 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.47 | -0.46 | -0.41 | -0.52 | -0.71 | |
Operating cash flow per share | -0.55 | -0.35 | -0.38 | -0.34 | -0.28 | |
Free cash flow per share | -0.55 | -0.35 | -0.38 | -0.34 | -0.28 | |
Cash per share | 3.28 | 2.94 | 2.55 | 2.23 | 1.95 | |
Book value per share | 3.64 | 3.27 | 2.94 | 2.54 | 1.93 | |
Tangible book value per share | 3.64 | 3.27 | 2.94 | 2.54 | 1.93 | |
Share holders equity per share | 3.64 | 3.27 | 2.94 | 2.54 | 1.93 | |
Interest debt per share | 0.61 | 0.47 | 0.49 | 0.48 | 0.47 | |
Market cap | 717.91M | 382.01M | 377.78M | 197.75M | 239.06M | |
Enterprise value | 679.8M | 331.52M | 350.13M | 169M | 214.08M | |
P/E ratio | -4.51 | -2.4 | -2.69 | -1.08 | -0.96 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -15.34 | -12.67 | -11.59 | -6.71 | -9.85 | |
PFCF ratio | -15.25 | -12.56 | -11.5 | -6.68 | -9.86 | |
P/B Ratio | 2.31 | 1.36 | 1.48 | 0.89 | 1.42 | |
PTB ratio | 2.31 | 1.36 | 1.48 | 0.89 | 1.42 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -14.71 | -7.62 | -9.26 | -3.62 | -3.37 | |
EV to operating cash flow | -14.53 | -11 | -10.74 | -5.73 | -8.82 | |
EV to free cash flow | -14.44 | -10.9 | -10.66 | -5.71 | -8.83 | |
Earnings yield | -0.06 | -0.1 | -0.09 | -0.23 | -0.26 | |
Free cash flow yield | -0.07 | -0.08 | -0.09 | -0.15 | -0.1 | |
Debt to equity | 0.16 | 0.15 | 0.17 | 0.19 | 0.25 | |
Debt to assets | 0.13 | 0.12 | 0.13 | 0.15 | 0.17 | |
Net debt to EBITDA | 0.82 | 1.16 | 0.73 | 0.62 | 0.39 | |
Current ratio | 10.28 | 9.58 | 10.27 | 9.31 | 4.92 | |
Interest coverage | -16.65 | 17.05 | 0 | 0 | 0 | |
Income quality | 1.09 | 0.71 | 0.93 | 0.65 | 0.39 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.19 | -0.18 | -0.17 | -0.07 | 0.02 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.18 | 5.83 | 5.18 | 5.47 | 5.57 | |
ROIC | -0.11 | -0.12 | -0.11 | -0.15 | -0.26 | |
Return on tangible assets | -0.1 | -0.11 | -0.11 | -0.16 | -0.26 | |
Graham Net | 2.39 | 2.13 | 1.81 | 1.51 | 1.1 | |
Working capital | 278.81M | 253.33M | 227.08M | 194.83M | 143.31M | |
Tangible asset value | 310.43M | 280.45M | 254.98M | 221.04M | 168.82M | |
Net current asset value | 232.86M | 212.9M | 187.34M | 155.83M | 105.1M | |
Invested capital | 0.16 | 0.15 | 0.17 | 0.19 | 0.25 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 4.72M | 6.97M | 6.7M | 2.61M | 1.34M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 222.33 | 409.95 | 211.7 | 53.16 | 102.62 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.4 | 0.22 | 0.43 | 1.69 | 0.88 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.14 | -0.14 | -0.21 | -0.37 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ALLK Frequently Asked Questions
What is Allakos Inc. stock symbol ?
Allakos Inc. is a US stock , located in Redwood city of Ca and trading under the symbol ALLK
Is Allakos Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $110.5. The lowest prediction is $3 and the highest is $218
What is ALLK stock prediction ?
With a median analyst target price of $3, 1 stock analysts have made 1 forecasts in last 90 days. $3 is the lowest and $3 is the greatest projection.
What is Allakos Inc. stock quote today ?
Allakos Inc. stock price is $1.265 today.
Is Allakos Inc. stock public?
Yes, Allakos Inc. is a publicly traded company.